Chardan analyst Daniil Gataulin lowered the firm’s price target on Gensight Biologics (GSGTF) to EUR 13 from EUR 15 and keeps a Buy rating on the shares. The company announced a delay to the Lumevoq European Medicines Agency decision, to Q1 of 2024 from Q3 of 2023, due to an operational issue at the third-party manufacturer Thermo Fisher Scientific (TMO) in the handling of the downstream process, the analyst tells investors in a research note. The firm says Gensight ‘s cash runway remains a concern.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TMO:
- Thermo Fisher raises quarterly dividend 17% to 35c per share
- Elektrofi announces collaboration with Thermo Fisher
- Jefferies says Catalent could be valued near $93 on average CDMO buyout multiple
- Thermo Fisher price target raised to $670 from $613 at Morgan Stanley
- Thermo Fisher price target raised to $711 from $690 at Cowen
